DEEP CELL REBUILD TECHNOLOGY – Ongoing clinical study in Shanghai
In December 2025, CELONIQUE and ULTIMA launched the DEEP CELL REBUILD TECHNOLOGY clinical study, which is currently ongoing in Shanghai.
The study involves 40 participants and is being conducted at the MAIO Beauty Clinic, with the professional support of the ROYAL Life Group.
The project is coordinated and supervised by Daniel Matthieu, CEO of CELONIQUE, who oversees the study to ensure consistent scientific standards and internationally aligned protocols.
Based on the interim observations collected so far, visible and measurable improvements are already being recorded. After the first treatments, a lifting effect can be detected through targeted muscle stimulation with ULTIMA, assessed using professional skin analysis devices.
In combination with iontophoresis and the CELONIQUE ION LIFT MULTI-PEPTIDE Gel, a clear improvement is being observed in inflammatory markers within deeper skin layers. Active ingredients such as collagen, Q10, peptides, vitamins and exosomes are delivered non-invasively into the basal cell layer responsible for skin regeneration.
Most participants show a noticeable reduction in pore size, decreased wrinkle depth and a smoother, more even complexion. With continued treatments, these effects appear to further improve.
Patient feedback has been very positive so far. The treatment is described as painless, comfortable and safe, with no risk of infection. Many participants choose to continue with follow-up sessions, as they find the method pleasant and well tolerated.